Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

Rhabdomyosarcoma (RMS) is a highly metastatic soft-tissue sarcoma that often develops resistance to current therapies, including vincristine. Since the existing treatments have not significantly improved survival, there is a critical need for new therapeutic approaches for RMS patients. FOXM1, a kno...

Descripción completa

Detalles Bibliográficos
Autores principales: Donovan, Johnny, Deng, Zicheng, Bian, Fenghua, Shukla, Samriddhi, Gomez-Arroyo, Jose, Shi, Donglu, Kalinichenko, Vladimir V., Kalin, Tanya V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933126/
https://www.ncbi.nlm.nih.gov/pubmed/36816948
http://dx.doi.org/10.3389/fonc.2023.1112859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933126/
https://www.ncbi.nlm.nih.gov/pubmed/36816948
http://dx.doi.org/10.3389/fonc.2023.1112859

Ejemplares similares